4. Deferred Revenue

We expect our current deferred revenue to be recognized as revenue within 12 months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately two years from June 30, 2026. This period of time represents an estimate of the ongoing sample testing for our customers' therapeutic development efforts.

Changes in deferred revenue during the six months ended June 30, 2026 were as follows (in thousands):


Deferred revenue balance at December 31, 2025	$	46,200
Additions to deferred revenue during the period		49,429
Revenue recognized during the period		(41,766	)
Deferred revenue balance at June 30, 2026	$	53,863

During the six months ended June 30, 2026, $19.0 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2025.